Corporate News     22-Jun-18
AstraZeneca receives marketing permission for Durvalumab (ImfinziTM) in India
AstraZeneca Pharma India announced that it has received Import & Market permission for Durvalumab (ImfinziTM) in India by the Drug Controller General of India (DCGI). The receipt of this permission paves way for the launch of durvalumab (ImfinziTM) in India, subject to the receipt of further related statutory approvals and licenses.

Durvalumab provides a treatment option for patient with locally advanced, unresectable Non-Small Cell Lung Cancer (NSCLC) and metastatic urothelial carcinoma.

Durvalumab is a patented product of AstraZeneca global.

Previous News
  Astrazeneca Pharma India standalone net profit declines 38.28% in the March 2023 quarter
 ( Results - Announcements 31-May-23   07:43 )
  Astrazeneca Pharma soars after receiving regulatory nod for importing Andexxa
 ( Hot Pursuit - 20-Jan-24   13:14 )
  Astrazeneca Pharma gets nod from CDSCO to import Olaparib film coated tablets
 ( Hot Pursuit - 22-Nov-23   11:07 )
  Astrazeneca Pharma India to hold board meeting
 ( Corporate News - 22-Jan-20   10:30 )
  Astrazeneca Pharma India announces board meeting date
 ( Corporate News - 02-Feb-22   11:28 )
  Astrazeneca Pharma India to convene board meeting
 ( Corporate News - 03-Nov-21   16:58 )
  Astrazeneca Pharma India to hold board meeting
 ( Corporate News - 19-May-21   09:45 )
  Astrazeneca Pharma rises on planning to launch Enhertu
 ( Hot Pursuit - 21-Dec-23   10:01 )
  Astrazeneca Pharma India standalone net profit declines 53.97% in the June 2017 quarter
 ( Results - Announcements 09-Aug-17   17:10 )
  AstraZeneca Pharma jumps after turnaround Q4 result
 ( Hot Pursuit - 28-May-15   09:45 )
  Astrazeneca Pharma India standalone net profit rises 184.76% in the March 2021 quarter
 ( Results - Announcements 25-May-21   17:28 )
Other Stories
  Tinna Trade raises Rs 49 cr to fund its growth plans
  06-Jul-24   11:10
  Integra Essentia announces merger with G G Engineering
  06-Jul-24   11:05
  Ugro Capital to raise Rs 75 cr via NCD issuance
  06-Jul-24   10:58
  Board of D.P. Abhushan approves preferential allotment of shares and warrants
  06-Jul-24   10:50
  Life Insurance Corporation of India invest Rs 14 cr in Sri Lankan subsidiary
  06-Jul-24   10:49
  High Energy Batteries (India) to discuss results
  06-Jul-24   10:29
  Havells India schedules board meeting
  06-Jul-24   10:29
  Axis Bank announces board meeting date
  06-Jul-24   10:29
  Mastek to conduct board meeting
  06-Jul-24   10:29
  Oriental Hotels to conduct board meeting
  06-Jul-24   10:29
Back Top